AmBisome

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Candidemia

Conditions

Candidemia, Invasive Candidiasis

Trial Timeline

May 1, 2007 → Jan 1, 2009

NCT ID

NCT00670657

About AmBisome

AmBisome is a approved stage product being developed by Gilead Sciences for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00670657. Target conditions include Candidemia, Invasive Candidiasis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00670657	Approved	Completed	May 1, 2007	Jan 1, 2009	Candidemia
NCT00326157	Phase 2	Completed	Jun 1, 2006	Nov 1, 2009	Fungus Diseases
NCT00362544	Approved	Completed	Oct 1, 2003	Mar 1, 2006	Leukemia
NCT00158730	Phase 3	Completed	Apr 1, 2003	Jan 1, 2005	Invasive Aspergillosis

Competing Products

9 competing products in Candidemia

See all competitors

Product	Company	Stage	Hype Score
micafungin + Micafungin + Caspofungin	Astellas Pharma	Approved	85
Micafungin	Astellas Pharma	Approved	85
Anidulafungin/Fluconazole	Pfizer	Phase 3	76
Anidulafungin + Voriconazole	Pfizer	Approved	84
Anidulafungin + Fluconazole	Pfizer	Phase 3	76
Anidulafungin	Pfizer	Phase 3	76
Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo	Basilea Pharmaceutica	Phase 3	72
APX001	Basilea Pharmaceutica	Phase 2	47
APX001	Basilea Pharmaceutica	Phase 2	47

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved